The global Vaccines & Drugs market gathered revenue around USD 2,271 Million in 2021 and market is set to grow USD 1,502 Million by the end of 2027 and is estimated to expand at a modest CAGR of 16.7% during the prediction period 2021 to 2027.The growth of the COVID vaccines market is attributed majorly to the rising number of people infected with COVID-19 and increasing funding for vaccine development. The growth of the COVID drugs market is primarily attributed to use of repurposed drugs for compassionate use, and the emergence of alternative therapies such as convalescent plasma therapy which were earlier used for treating epidemic diseases such as SARS, MERS, and H1N1. Moreover, collaborations between global organizations and governments of various nations to promote the supply of essential drugs and medical supplies are fueling the market growth.
This research report purposes at stressing the most lucrative growth prospects. The aim of the research report is to provide an inclusive valuation of the Vaccines & Drugs market and it encompasses thoughtful visions, actualities, industry-validated market findings, historic data, and prognoses by means of appropriate set of assumptions and practice. Global Vaccines & Drugs market report aids in comprehending market structure and dynamics by recognizing and scrutinizing the market sectors and predicted the global market outlook.
COVID-19 Impact Assessment on Market Landscape
The report comprises the scrutiny of COVID-19 lock-down impact on the income of market leaders, disrupters and followers. Since lock down was instigated differently in diverse regions and nations, influence of same is also dissimilar across various industry verticals. The research report offers present short-term and long-term influence on the market to assist market participants across value chain makers to formulate the framework for short term and long-lasting tactics for recovery and by region.
Vaccines & Drugs market report empower readers with all-inclusive market intelligence and offers a granular outline of the market they are operational in. Further this research study delivers exceptional combination of tangible perceptions and qualitative scrutiny to aid companies accomplishes sustainable growth. This report employs industry-leading research practices and tools to assemble all-inclusive market studies, intermingled with pertinent data. Additionally, this report also emphases on the competitive examination of crucial players by analyzing their product portfolio, pricing, gross margins, financial position, growth approaches, and regional occurrence.
Report Highlights | Details |
Market Size | US$ 1,502 Million by 2027 |
Growth Rate | CAGR of 16.7% From 2021 to 2027 |
Base Year | 2020 |
Historic Data | 2017 to 2020 |
Forecast Period | 2021 to 2027 |
Segments Covered | Vaccine,Therapeutic drugs |
Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA) |
Companies Mentioned | Pfizer Inc. (US), Johnson & Johnson Services, Inc (US), GlaxoSmithKline plc. (UK), Sanofi (France) Serum Institute of India (India), among others. Gilead Sciences, Inc. (US), Sanofi (France), F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Janssen Pharmaceuticals, Inc. (Belgium) |
Competitive Rivalry
Foremost players in the market are attentive on adopting corporation strategies to enhance their market share. Some of the prominent tactics undertaken by leading market participants in order to sustain the fierce market completion include collaborations, acquisitions, substantial spending in R&D and the improvement of new-fangled products or reforms among others.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
Significant Market Participants Operational in the Vaccines & Drugs Market are:
The leading players in the Vaccines & Drugs Market are Pfizer Inc. (US), Johnson & Johnson Services, Inc (US), GlaxoSmithKline plc. (UK), Sanofi (France) Serum Institute of India (India), among others. Major players in the COVID-19 drugs market include Gilead Sciences, Inc. (US), Sanofi (France), F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Janssen Pharmaceuticals, Inc. (Belgium) among others.
Unravelling the Critical Segments
This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects including product type, application/end-user, and region. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for period 2017 to 2027 and covers subsequent region in its scope:
Vaccine
The current pipeline of vaccines by phase by companies
Competitive landscape (top players in vaccines)
Macroeconomic indicators
Post COVID-19 vaccine approval scenario
Strategies to ramp up production at a pandemic level
Covid-19 vaccine market estimation
Therapeutic drugs
The current pipeline of drugs by phase by companies
Competitive landscape (top players in COVID-19 therapeutic drugs)
Macroeconomic indicators
Post COVID-19 approval scenario
Strategies to ramp up production at a pandemic level
Covid-19 vaccine market estimation
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Highlights of the Report:
Research Methodology
In the study, a unique research methodology is utilized to conduct extensive research on the growth of the Vaccines & Drugs market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the conclusions.
Secondary resources referred to by analysts during the production of the Vaccines & Drugs market study are as follows - statistics from government organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, all of whom have contributed to the development of this report as a primary resource.
Comprehensive information acquired from primary and secondary resources acts as a validation from companies in the market, and makes the projections on the growth prospects of the Vaccines & Drugs markets more accurate and reliable.
Secondary Research
It involves company databases such as Hoover's: This assists us recognize financial information, structure of the market participants and industry competitive landscape.
The secondary research sources referred in the process are as follows:
Primary Research
Primary research includes face-to face interviews, online surveys, and telephonic interviews.
Industry participants involved in this research study include:
The study objectives of this report are:
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Vaccines & Drugs Market, By Vaccine
7.1. Vaccines & Drugs Market, by Vaccine, 2021-2027
7.1.1. Competitive landscape (top players in vaccines)
7.1.1.1. Market Revenue and Forecast (2016-2027)
7.1.2. Macroeconomic indicators
7.1.2.1. Market Revenue and Forecast (2016-2027)
7.1.3. Post COVID-19 vaccine approval scenario
7.1.3.1. Market Revenue and Forecast (2016-2027)
7.1.4. Strategies to ramp up production at a pandemic level
7.1.4.1. Market Revenue and Forecast (2016-2027)
7.1.5. Covid-19 vaccine market estimation
7.1.5.1. Market Revenue and Forecast (2016-2027)
Chapter 8. Global Vaccines & Drugs Market, Therapeutic drugs
8.1. Vaccines & Drugs Market, Therapeutic drugs, 2021-2027
8.1.1. Competitive landscape (top players in COVID-19 therapeutic drugs)
8.1.1.1. Market Revenue and Forecast (2016-2027)
8.1.2. Macroeconomic indicators
8.1.2.1. Market Revenue and Forecast (2016-2027)
8.1.3. Post COVID-19 approval scenario
8.1.3.1. Market Revenue and Forecast (2016-2027)
8.1.4. Strategies to ramp up production at a pandemic level
8.1.4.1. Market Revenue and Forecast (2016-2027)
8.1.5. Covid-19 vaccine market estimation
8.1.5.1. Market Revenue and Forecast (2016-2027)
Chapter 9. Global Vaccines & Drugs Market, Regional Estimates and Trend Forecast
9.1. North America
9.1.1. Market Revenue and Forecast, by Vaccine (2016-2027)
9.1.2. Market Revenue and Forecast, Therapeutic drugs (2016-2027)
9.1.3. U.S.
9.1.3.1. Market Revenue and Forecast, by Vaccine (2016-2027)
9.1.3.2. Market Revenue and Forecast, Therapeutic drugs (2016-2027)
9.1.4. Rest of North America
9.1.4.1. Market Revenue and Forecast, by Vaccine (2016-2027)
9.1.4.2. Market Revenue and Forecast, Therapeutic drugs (2016-2027)
9.2. Europe
9.2.1. Market Revenue and Forecast, by Vaccine (2016-2027)
9.2.2. Market Revenue and Forecast, Therapeutic drugs (2016-2027)
9.2.3. UK
9.2.3.1. Market Revenue and Forecast, by Vaccine (2016-2027)
9.2.3.2. Market Revenue and Forecast, Therapeutic drugs (2016-2027)
9.2.4. Germany
9.2.4.1. Market Revenue and Forecast, by Vaccine (2016-2027)
9.2.4.2. Market Revenue and Forecast, Therapeutic drugs (2016-2027)
9.2.5. France
9.2.5.1. Market Revenue and Forecast, by Vaccine (2016-2027)
9.2.5.2. Market Revenue and Forecast, Therapeutic drugs (2016-2027)
9.2.6. Rest of Europe
9.2.6.1. Market Revenue and Forecast, by Vaccine (2016-2027)
9.2.6.2. Market Revenue and Forecast, Therapeutic drugs (2016-2027)
9.3. APAC
9.3.1. Market Revenue and Forecast, by Vaccine (2016-2027)
9.3.2. Market Revenue and Forecast, Therapeutic drugs (2016-2027)
9.3.3. India
9.3.3.1. Market Revenue and Forecast, by Vaccine (2016-2027)
9.3.3.2. Market Revenue and Forecast, Therapeutic drugs (2016-2027)
9.3.4. China
9.3.4.1. Market Revenue and Forecast, by Vaccine (2016-2027)
9.3.4.2. Market Revenue and Forecast, Therapeutic drugs (2016-2027)
9.3.5. Japan
9.3.5.1. Market Revenue and Forecast, by Vaccine (2016-2027)
9.3.5.2. Market Revenue and Forecast, Therapeutic drugs (2016-2027)
9.3.6. Rest of APAC
9.3.6.1. Market Revenue and Forecast, by Vaccine (2016-2027)
9.3.6.2. Market Revenue and Forecast, Therapeutic drugs (2016-2027)
9.4. MEA
9.4.1. Market Revenue and Forecast, by Vaccine (2016-2027)
9.4.2. Market Revenue and Forecast, Therapeutic drugs (2016-2027)
9.4.3. GCC
9.4.3.1. Market Revenue and Forecast, by Vaccine (2016-2027)
9.4.3.2. Market Revenue and Forecast, Therapeutic drugs (2016-2027)
9.4.4. North Africa
9.4.4.1. Market Revenue and Forecast, by Vaccine (2016-2027)
9.4.4.2. Market Revenue and Forecast, Therapeutic drugs (2016-2027)
9.4.5. South Africa
9.4.5.1. Market Revenue and Forecast, by Vaccine (2016-2027)
9.4.5.2. Market Revenue and Forecast, Therapeutic drugs (2016-2027)
9.4.6. Rest of MEA
9.4.6.1. Market Revenue and Forecast, by Vaccine (2016-2027)
9.4.6.2. Market Revenue and Forecast, Therapeutic drugs (2016-2027)
9.5. Latin America
9.5.1. Market Revenue and Forecast, by Vaccine (2016-2027)
9.5.2. Market Revenue and Forecast, Therapeutic drugs (2016-2027)
9.5.3. Brazil
9.5.3.1. Market Revenue and Forecast, by Vaccine (2016-2027)
9.5.3.2. Market Revenue and Forecast, Therapeutic drugs (2016-2027)
9.5.4. Rest of LATAM
9.5.4.1. Market Revenue and Forecast, by Vaccine (2016-2027)
9.5.4.2. Market Revenue and Forecast, Therapeutic drugs (2016-2027)
Chapter 10. Company Profiles
10.1. Pfizer Inc.
10.1.1. Company Overview
10.1.2. Product Offerings
10.1.3. Financial Performance
10.1.4. Recent Initiatives
10.2. Johnson & Johnson Services, Inc
10.2.1. Company Overview
10.2.2. Product Offerings
10.2.3. Financial Performance
10.2.4. Recent Initiatives
10.3. Johnson & Johnson Services, Inc
10.3.1. Company Overview
10.3.2. Product Offerings
10.3.3. Financial Performance
10.3.4. Recent Initiatives
10.4. Sanofi
10.4.1. Company Overview
10.4.2. Product Offerings
10.4.3. Financial Performance
10.4.4. Recent Initiatives
10.5. Serum Institute of India
10.5.1. Company Overview
10.5.2. Product Offerings
10.5.3. Financial Performance
10.5.4. Recent Initiatives
10.6. Serum Institute of India
10.6.1. Company Overview
10.6.2. Product Offerings
10.6.3. Financial Performance
10.6.4. Recent Initiatives
10.7. Sanofi
10.7.1. Company Overview
10.7.2. Product Offerings
10.7.3. Financial Performance
10.7.4. Recent Initiatives
10.8. F. Hoffmann-La Roche Ltd
10.8.1. Company Overview
10.8.2. Product Offerings
10.8.3. Financial Performance
10.8.4. Recent Initiatives
10.9. Merck KGaA
10.9.1. Company Overview
10.9.2. Product Offerings
10.9.3. Financial Performance
10.9.4. Recent Initiatives
10.10. Janssen Pharmaceuticals, Inc.
10.10.1. Company Overview
10.10.2. Product Offerings
10.10.3. Financial Performance
10.10.4. Recent Initiatives
Chapter 11. Research Methodology
11.1. Primary Research
11.2. Secondary Research
11.3. Assumptions
Chapter 12. Appendix
12.1. About Us
12.2. Glossary of Terms